Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.

Hamid Emamekhoo,Mark R. Olsen,Bradley Curtis Carthon,Alexandra Drakaki,Ivor John Percent,Ana M. Molina,Daniel C. Cho,Johanna C. Bendell,Lucio N. Gordan,Arash Rezazadeh Kalebasty,Daniel J. George,Thomas E. Hutson,Edward Arrowsmith,Joshua Zhang,Jesus Zoco,Jennifer L. Johansen,David Leung,Scott S. Tykodi

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.

2021

Hamid Emamekhoo
Mark R. Olsen
Bradley Curtis Carthon
Alexandra Drakaki
Ivor John Percent
Ana M. Molina
Daniel C. Cho
Johanna C. Bendell
Lucio N. Gordan
Arash Rezazadeh Kalebasty
Daniel J. George
Thomas E. Hutson
Edward Arrowsmith
Joshua Zhang
Jesus Zoco
Jennifer L. Johansen
David Leung
Scott S. Tykodi

4515Background: Combination therapy with nivolumab plus ipilimumab (NIVO+IPI) has demonstrated long-term efficacy and tolerability in patients with previously untreated advanced renal cell carcinom...

Keywords:

Ipilimumab
Medicine
Internal medicine
Nivolumab
Tolerability
Combination therapy
Renal cell carcinoma
Oncology
in patient
Checkmate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations